Stocktoria
Septerna, Inc. SEPN
Septerna, Inc. (SEPN) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $46.0M at a -106.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.544 |
| Retained earnings / assets | -0.281 |
| EBIT / assets | -0.115 |
| Equity / liabilities | 1.783 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SEPN | Septerna, Inc. | 4/9 | 3.75 | — | — |
| PTGX | Protagonist Therapeutics, Inc | 4/9 | 13.41 | — | -89.4% |
| AQST | Aquestive Therapeutics, Inc. | 2/9 | -8.08 | — | -22.6% |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | 4/9 | -0.86 | — | +17.6% |
| XLO | Xilio Therapeutics, Inc. | 4/9 | -6.58 | — | — |
| GOSS | Gossamer Bio, Inc. | — | — | — | -57.7% |
| WVE | Wave Life Sciences Ltd. | 2/9 | 1.15 | — | -60.5% |
About Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
FAQ
Is SEPN financially healthy?
Septerna, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does SEPN pay a dividend?
No, Septerna, Inc. does not currently pay a dividend.
How profitable is SEPN?
In FY2025, Septerna, Inc. had a net margin of -106.4% and a return on equity of -12.8%.
What is the analyst price target for SEPN?
The average Wall-Street price target for Septerna, Inc. is $44.89, about 6.9% below the recent price, from 9 analysts (consensus: strong buy).
Is SEPN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Septerna, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.